Publications by authors named "Antoine Ferry"
Article Synopsis
- - Repurposing existing medicines can quickly address unmet therapeutic needs, especially for rare diseases and health emergencies, but challenges can prevent drugs from reaching patients.
- - Obstacles in accessing drug data and complex clinical trial processes can hinder the successful repurposing of drugs, even if promising results are found.
- - To effectively overcome these challenges, the discussion emphasized the need for public-private partnerships that provide adequate funding and support for drug repurposing projects through to marketing approval.
Objective: Eye drops of aganirsen, an antisense oligonucleotide preventing insulin receptor substrate-1 expression, inhibited corneal neovascularization in a previous dose-finding phase II study. We aimed to confirm these results in a phase III study and investigated a potential clinical benefit on visual acuity (VA), quality of life (QoL), and need for transplantation.
Design: Multicenter, double-masked, randomized, placebo-controlled phase III study.
Increased inflammation and aberrant angiogenesis underlie psoriasis. Here, we report that the inhibition of insulin receptor substrate-1 (IRS-1) expression with aganirsen resulted in a dose-dependent reduction (P < 0.0001) in IRS-1 protein in the cytoplasm, while IRS-1 protein remained quantitatively unchanged in the perinuclear environment.
View Article and Find Full Text PDFPurpose: Aganirsen, an antisense oligonucleotide inhibiting insulin receptor substrate (IRS)-1 expression, has been shown to promote the regression of pathologic corneal neovascularization in patients. In this study, the authors aimed to demonstrate the antiangiogenic activity of aganirsen in animal models of retinal neovascularization.
Methods: Eyedrops of aganirsen were applied daily in nonhuman primates after laser-induced choroidal neovascularization (CNV; model of wet age-related macular degeneration [AMD]) and in newborn rats after oxygen-induced retinopathy (OIR; model of ischemic retinopathy).